Nov 5, 2013 by Kanak KantiIs This Regeneron's Biggest Opportunity?Alirocumab represents a long-term opportunity to Regeneron and its partner Sanofi.
Oct 23, 2013 by Kanak KantiWhy This Acquisition Makes SenseMesoblast's acquisition of Osiris Therapeutics' MSC business makes strategic sense.
Oct 10, 2013 by Kanak KantiA Solid Health Care Stock to Watch?With its solid business, Baxter International is a stock to watch for investors looking for dividends.
Oct 4, 2013 by Kanak KantiThis Company Is Focused on Delivering Value to Patients and ShareholdersDyax is looking to capitalize on its unique phage display technology (companies discussed in this article include VPHM, SHPG, DYAX).
Oct 3, 2013 by Kanak KantiWhy AbbVie's Global Alliance With Galapagos Is Good News for InvestorsAbbVie's global alliance with Galapagos will further boost the company's financial performance.
Oct 1, 2013 by Kanak KantiAlnylam's Biggest OpportunitiesAlnylam Pharmaceuticals is an emerging leader in a new gene-based therapy.
Sep 30, 2013 by Kanak Kanti3 Stocks to Watch in the Urology Devices MarketHow Endo Health is performing in the urology devices market.
Sep 30, 2013 by Kanak KantiAbraxane's Approval for Pancreatic Cancer Is a Major Milestone for CelgeneAbraxane approval for pancreatic cancer will boost Celgene's top-line.
Sep 23, 2013 by Kanak KantiWhy You Should Get Excited About This Health Care CompanySteris offers steady growth in multiple markets.
Sep 23, 2013 by Kanak KantiWhy Teva's Generic Version of Xeloda Has Significant PotentialTeva's generic Xeloda may be a game changer for the company.
Sep 20, 2013 by Kanak KantiAn Excellent Investment in the Biotech Space?Exelixis might be a stock to watch.
Sep 20, 2013 by Kanak Kanti4 Reasons to Buy This Biotechnology StockIsis has many positives for investors.
Sep 12, 2013 by Kanak KantiTime to Bet on This Biotech Spinoff?Theravance is not too healthy right now.
Sep 11, 2013 by Kanak KantiWill History Repeat for Inhaled Insulin?Mannkind's Afrezza is better than Exubera, but by how much?
Sep 11, 2013 by Kanak Kanti3 Justifications for the High Cost of GattexGattex may seem pricey, but it will still sell.
Sep 11, 2013 by Kanak KantiWhat Does Roche's Inovio Deal Mean for Investors?Inovio is not for the short-sighted.
Sep 11, 2013 by Kanak KantiCheers and Jeers for Amgen's PipelineAmgen's heart drug may be revived, despite failure, all puns intended.
Sep 10, 2013 by Kanak Kanti3 Reasons to Like This Critical Care CompanyA few reasons why The Medicines Company is investment grade.
Sep 9, 2013 by Kanak KantiOutsourcing Your LaboratoryCovance is doing well with its contract research business.
